Protox Therapeutics uses genetic engineering to transform naturally occurring proteins into novel targeted therapeutics for the treatment of various cancers and other proliferative diseases. Protox is advancing a pipeline of clinical-stage product candidates derived from its PORxin™ and INxin™ technology platforms. Protox’s lead drugs currently in clinical development include PRX321 for primary brain cancer (glioblastoma multiforme and astrocytoma) and PRX302 for the treatment of localized prostate cancer and benign prostatic hyperplasia (BPH, commonly known as enlarged prostate).

Dr. Fahar Merchant, President and CEO, Protox Therapeutics interiewed on BNN Small Caps
Wednesday, March 26, 2008